Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2017-11-10
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ibrutinib when given together
with idarubicin and cytarabine in treating patients with acute myeloid leukemia that has
returned after a period of improvement or has not responded to previous treatment. Ibrutinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving ibrutinib together with idarubicin and cytarabine may
kill more cancer cells.